Follow-up study of adolescents exposed to Di Phthalate as neonates on extracorporeal membrane oxygenation support

Environmental Health Perspectives, Sept, 2004 by Khodayar Rais-Bahrami, Susan Nunez, Mary E. Revenis, Naomi L.C. Luban, Billie L. Short

Roth B, Herkenrath P, Lehmann H J, Ohies HD, Homig H J, Benz-Bohm G, et al. 1988. Di-(2-ethylhexyl)-phthalate as plasticizer in PVC respiratory tubing systems: indications of hazardous effects on pulmonary function in mechanically ventilated, preterm infants. Eur J Pediatr 147:41-46.

Rubin RJ, Schiffer CA. 1976. Fate in humans of the plasticizer, di-2-ethylhexyl phthalate, arising from transfusion of platelets stored in vinyl plastic bags. Transfusion 16:330-335.

Shneider B, Schena J, Truog R, Jacobson M, Kevy S. 1989. Exposure to di (2-ethylhexyl) phthalate in infants receiving extracorporeal membrane oxygenation. N Engl J Med 320:1563.

Tanner JM. 1975. Growth and endocrinology of the adolescent. In: Endocrine and Disease of Childhood (Gardner LJ II, ed). Philadelphia:W.B. Saunders, 14-64.

Thomas JA, Schein LG, Gupta PK, McCafferty RE, Felice PR, Donovan MP. 1979. Failure of monoethylhexyl phthalate to cause teratogenic effects in offspring of rabbits. Toxicol Appl Pharmacol 51:523-528.

Tickner JA, Schettler T, Guidotti T, McCaliy M, Rossi M. 2001. Health risks posed by use of di-2-ethylhexyl phthalate (DEHP) in PVC medical devices: a critical review. Am J Ind Med 39:100-111.

Ward JM, Peters JM, Perella CM, Gonzalez FJ. 1998. Receptor and nonreceptor mediated organ-specific toxicity of DEHP in peroxisome proliferator-activated receptor alpha-null mice. Toxicol Pathol 26:240-246.

Khodayar Rais-Bahrami, (1) Susan Nunez, (2) Mary E. Revenis, (1) Naomi L.C. Luban, (3) and Billie L. Short (1)

(1) Departments of Neonatology, (2) Endocrinology, and (3) Transfusion Medicine, Children's National Medical Center and The George Washington University School of Medicine, Washington, DC, USA

Address correspondence to K. Rais-Bahrami, Department of Neonatology, Children's National Medical Center, 111 Michigan Ave., NW, Washington, DC 20010 USA. Telephone: (202) 884-4764. Fax: (202) 884-3459. E-mail: Kraisbah@CNMC.org

The study was supported by grant M01-RR13297 from the General Clinical Research Center, Program of the National Center for Research Resources, National Institutes of Health, Department of Health and Human Services.

The authors declare they have no competing financial interests.

Received 8 December 2003; accepted 7 April 2004.

Table 1. Results of sexual hormones in female subjects matched for
Tanner stage [mean value (normal reference range)].

Females (n)    Tanner stage         LH (IU/L)           FSH (IU/L)

4                   4          6.05 (0.72-15.01)    4.58 (1.26-7.37)
2                   5           3.7 (0.30-29.38)    2.65 (1.02-9.24)

Females (n)    Estradiol (pg/mL)

4                48.75 (25-345)
2                118.5 (25-410)

Table 2. Results of sexual hormones, testicular volume, and phallic
length in male subjects matched for Tanner stage [mean value (normal
reference rangell.

             Tanner
Males (n)    stage        LH (IU/L)           FSH (IU/L)

4             2-3      1.83 (0.26-3.74)    2.40 (0.72-10.37)
9             4-5      3.02 (0.55-7.00)    3.61 (1.70-7.00)

             Testosterone     Testicular     Phallic length
Males (n)       (ng/dL)       volume (mL)         (cm)

4            119 (15-280)     11 (5-10)       8.0 (6.3-8.6)
9            387 (105-800)    22 (20-29)     11.2 (8.6-9.9)